SEC Form 4/A · accession 0001209191-17-057662
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
John F Crowley
Officer — Chairman & CEO · Director
Period of report
Oct 17, 2017
Accepted (ET)
Oct 20, 2017 · 5:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 17, 2017 | M | 52,722 | $14.75 | A | 380,723 | D | |
| Common Stock | Oct 17, 2017 | S | 52,722 | $14.75 | D | 328,001 | D | |
| Common StockF2 | Oct 18, 2017 | M | 19,013 | $14.7503 | A | 347,014 | D | |
| Common StockF3 | Oct 18, 2017 | S | 19,013 | $14.7503 | D | 328,001 | D | |
| Common Stock | holding | — | — | — | 64,895 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $3.53 | Oct 17, 2017 | M | 52,722 | D | Jan 28, 2017 | Jan 28, 2023 | Common Stock | 52,722 | 39,521 | D |
| Stock Options (right to buy) | $3.53 | Oct 18, 2017 | M | 19,013 | D | Jan 28, 2017 | Jan 28, 2023 | Common Stock | 19,013 | 20,508 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
- F2This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Remarks
This Form 4 amendment corrects the reporting person's Remarks from the originally filed Form 4. The Remarks should read as follows: Shares were sold to fund the "Megan K. Crowley 2016 Special Needs Trust", a trust for the benefit of Mr. Crowley's child, with the balance of the proceeds used for general estate planning purposes. The total shares sold represented less than 14% of Mr. Crowley's holdings of securities of the company and after these transactions, Mr. Crowley's percentage of shares beneficially owned is 1% of the company's outstanding shares.